Novonesis lifts full-year guidance after strong half-year performance
In newly released half-year results, Novonesis delivered a 9% organic sales growth, up from 8% seen in the second quarter. The company has narrowed its full-year outlook range to 6–8% organic sales growth (previously 5–8%).
Excluding the exit from certain countries, the 2025 outlook is placed at 7–9% (previously 6–9%).
“I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth,” says Ester Baiget, president and CEO of Novonesis.
Baiget also highlighted “solid profitability” for the biosolutions specialist, despite strong headwinds from currencies. “With a strong foundation in place, we are well-positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what makes Novonesis unique, further strengthening our position while expanding the biosolutions market.”
Half-year highlights
Novonesis’ Food & Health and Planetary Health segments contributed significantly to half-year results, with organic sales growth of 10% and 9%, respectively.
In terms of geographical performance, emerging markets outperformed with 12% organic sales growth, compared to 8% in developed markets.
The company also successfully achieved a 100% run rate for cost synergies, an increase from the previous 80%. This contributed to a higher adjusted EBITDA margin of 37.4%, which represents a 210 basis point increase.
Adjusted net profit also saw a notable increase of 23%. The NIBD/EBITDA ratio was 2.1x, a figure that includes the recent acquisition of dsm-firmenich’s part of the Feed Enzyme Alliance.
Additionally, the €100 million (~US$11.7 million) share buyback program was completed on June 27.
Narrowing sales outlook for 2025
The adjusted EBITDA margin is maintained at 37–38% despite strong currency headwinds.
The company has approved an interim dividend of DKK 2.25 (US$0.45)) for the first half of 2025.
Novonesis also revealed its long-term financial targets toward 2030, which are detailed in the Company Announcement on the 2030 “GROW” strategy, dated August 20, 2025.
This strategy will be presented and discussed during the extended H1 2025 conference call on August 21, at 9 a.m. CET.
In recent technological activities, Novonesis’ partner, 21st.Bio launched a new development program for animal-free bovine alpha-lactalbumin made using precision fermentation with an exclusive license for the high-yield microbial strain from Novonesis.
Novonesis also released an extensive peer-reviewed review gathering decades of research into its BB-12 strain (Bifidobacterium animalis subsp. lactis), one of the most thoroughly researched probiotics. The singular resource encompasses the strain’s mechanisms of action, clinical efficacy, and its relevance across all stages of life.
